Anthony Thomas McLellanShow email address
Department of Psychiatry (Emeritus), Perelman School of Medicine, University of Pennsylvania, Philadelphia | Treatment Research Institute, Philadelphia, Pennsylvania 19106; ...
Is this your profile? Claim your profile Copy URL Embed Link to your profile
Anthony Thomas McLellan:Expert Impact
Concepts for whichAnthony Thomas McLellanhas direct influence:Substance abuse,Addiction treatment,Addiction severity,Cocaine dependence,Substance disorders,Drug abuse,Conditioned responses,Treatment services.
Anthony Thomas McLellan:KOL impact
Concepts related to the work of other authors for whichfor which Anthony Thomas McLellan has influence:Substance abuse,Chronic pain,Mental health,Alcohol dependence,United states,Drug users,Addiction severity.
KOL Resume for Anthony Thomas McLellan
Department of Psychiatry (Emeritus), Perelman School of Medicine, University of Pennsylvania, Philadelphia
Treatment Research Institute, Philadelphia, Pennsylvania 19106; email:
Treatment Research Institute, Philadelphia, PA 19106, USA.
Treatment Research Institute ; University of Pennsylvania School of Medicine.
University of Pennsylvania, Philadelphia, PA, United States
Treatment Research Institute Philadelphia USA
Treatment Research Institute, 600 Public Ledger Building, 150 S. Independence Mall, 19106, Philadelphia, PA, USA
Penn Center for Substance Abuse Solutions, University of Pennsylvania, Philadelphia, PA, USA
University of Pennsylvania, School of Medicine, Philadelphia, PA, USA
White House Office of National Drug Control Policy, Washington, DC 20503, USA
Department of Psychiatry, University of Pennsylvania
Treatment Research Institute, Phildelphia PA, USA
The Treatment Research Institute (Dr McLellan)
Treatment Research Institute, 600 Public Ledger Building, 150 S. Independence Mall West, Philadelphia, PA 19106-3475, USA
University of Pennsylvania, Center for Studies of Addiction 3900 Chestnut St. Philadelphia, PA 19104, United States
The Treatment Research Institute (TRI), Philadelphia, PA 19106, USA
The Treatment Research Institute, University of Pennsylvania, Philadelphia, PA 19106, USA
University of Pennsylvania Center for Studies of Addiction, Philadelphia, Pennsylvania
Treatment Research Institute and University of Pennsylvania School of Medicine, 600 Public Ledger Boulevard, 150 S. Independence Mall, West Philadelphia, PA 19106, USA
Department of Psychiatry, University of Pennsylvania, and Treatment Research Institute, Philadelphia, PA, USA
Treatment Research Institute at the University of Pennsylvania
Address correspondence to Michael T. French, Ph.D., Associate Professor, Department of Epidemiology and Public Health, University of Miami (D93), 1801 NW 9th Avenue, Third Floor, Miami, FL 33136. Helena J. Salomé M.A., is a Senior Research Associate, Health Services Research Center, University of Miami, Miami, FL. Jody L. Sindelar, Ph.D., is an Associate Professor, School of Public Health, Yale University, New Haven, CT, and National Bureau of Economic Research. A. Thomas McLellan, Ph.D., is a Professor, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, and Treatment Research Institute, Philadelphia, PA. This article, submitted to
Treatment Research Institute, Philadelphia, PA, USA.
Department of Psychiatry, University of Pennsylvania, School of Medicine, 19106, Philadelphia, Pennsylvania, USA
University of Pennsylvania School of Medicine and Veterans Affairs Medical Center, 19104, Philadelphia, Pennsylvania
Philadelphia Veterans Affairs Medical Center Department of Psychiatry, North Wales, Pennsylvania
Penn-VA Center for Studies of Addiction and the Treatment Research Institute at the University of Pennsylvania, 600 Public Ledger Bldg., 150 South Independence Mall, Philadelphia, PA 19106, USA
Treatment Research Center, University of Pennsylvania School of Medicine
Veterans Affairs Medical Center, Philadelphia, Pennsylvania
Treatment Research Institute at the University of Pennsylvania, Philadelphia PA, USA
Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA USA
|followup ccm patients||#1|
|destructive character addiction||#1|
|alcohol medical treatment||#1|
|pathological detoxification fear||#1|
|severity addiction severity||#1|
|confirmatory components analysis||#1|
|early postdischarge behaviors||#1|
|design methodological advantages||#1|
|suspected differences samples||#1|
|counselors concrete method||#1|
|medical psychiatric problems||#1|
|local community circumstances||#1|
|agreement summary scores||#1|
|design 1 development||#1|
|severity clinical sample||#1|
|state licensing boards||#1|
|alternative asis role||#1|
|adults aod disorders||#1|
|programs 580 patients||#1|
|addiction severity client||#1|
|addiction ancillary services||#1|
|admission psychiatric status||#1|
|clinical detection detection||#1|
|detox fear subjects||#1|
|contemporary drug policies||#1|
|month day hospital||#1|
|client caseload distribution||#1|
|9 months postadmission||#1|
|chain referral technique||#1|
|comorbidity male methadone||#1|
|counselor average methadone||#1|
|clinical impact work||#1|
|potential implications clinicians||#1|
|prescription drugs risks||#1|
|focused continuing fcc||#1|
|tsr6 testretest reliabilities||#1|
|health improved identification||#1|
|Sign-in to see all concepts, it's free!|
Prominent publications by Anthony Thomas McLellan
A structured instrument for estimating the economic cost of drug abuse treatment The Drug Abuse Treatment Cost Analysis Program (DATCAP)
[ PUBLICATION ]
Drug abuse treatment programs need to know the cost of the services they provide. Indeed, continued public and private funding is now being linked to cost and performance measures, and programs can use financial data to improve organizational efficiency. However, one of the dangers of promoting cost studies at treatment programs is that most program staff are not technically prepared to perform a cost analysis and little user-friendly information is available to offer assistance. ...
|Known for Treatment Cost | Drug Abuse | Analysis Program | Financial Data | Companion Instrument|
Benefit‐Cost Analysis of Addiction Treatment: Methodological Guidelines and Empirical Application Using the DATCAP and ASI
[ PUBLICATION ]
OBJECTIVE: To provide detailed methodological guidelines for using the Drug Abuse Treatment Cost Analysis Program (DATCAP) and Addiction Severity Index (ASI) in a benefit-cost analysis of addiction treatment.
DATA SOURCES/STUDY SETTING: A representative benefit-cost analysis of three outpatient programs was conducted to demonstrate the feasibility and value of the methodological guidelines.
STUDY DESIGN: Procedures are outlined for using resource use and cost data collected with the ...
|Known for Addiction Treatment | Cost Analysis | Methodological Guidelines | Economic Benefit | Outcome Measures|
[ PUBLICATION ]
BACKGROUND: Monitoring the quality and availability of alcohol and other drug (AOD) services must be a central tenet of any health-related performance measurement system. The Washington Circle Group (WCG), which was convened by the Center for Substance Abuse Treatment Office of Managed Care in March 1998, has developed a core set of performance measures for AOD services for public- and private-sector health plans. It is also collaborating with a broad range of stakeholders to ensure ...
|Known for Performance Measures | Drug Services | Health Plans | Treatment Engagement | Washington Circle|
Estimating the client costs of addiction treatment: first findings from the client drug abuse treatment cost analysis program (Client DATCAP)
[ PUBLICATION ]
The costs of addiction treatment services are an important determinant of the cost-effectiveness of a program, and therefore, of relevance to addiction treatment providers, insurance companies and, patients. Several methods have been developed to estimate the costs of substance abuse treatment services. One such method is the drug abuse treatment cost analysis program (DATCAP), which collects resource use and cost data from the treatment program perspective and has been used in numerous ...
|Known for Client Datcap | Treatment Cost | Drug Abuse | Analysis Program | Preliminary Findings|
OBJECTIVE: OxyContin and other pharmaceutical opioids have been given special attention in the media, who frequently describe problematic users of the drug as previously drug-naive individuals who become addicted following legitimate prescriptions for medical reasons. The purpose of this study was to characterize the nature and origins of pharmaceutical opioid addiction among patients presenting at substance abuse treatment programs.
METHOD: The authors evaluated the prevalence and ...
|Known for Oxycontin Abuse | Treatment Substance | Pharmaceutical Opioids | Opioid Addiction | Drug Prescriptions|
Drug Dependence, a Chronic Medical Illness: Implications for Treatment, Insurance, and Outcomes Evaluation
[ PUBLICATION ]
The effects of drug dependence on social systems has helped shape the generally held view that drug dependence is primarily a social problem, not a health problem. In turn, medical approaches to prevention and treatment are lacking. We examined evidence that drug (including alcohol) dependence is a chronic medical illness. A literature review compared the diagnoses, heritability, etiology (genetic and environmental factors), pathophysiology, and response to treatments (adherence and ...
|Known for Drug Dependence | Chronic Medical | Medication Adherence | Health Problem | Environmental Factors|
OBJECTIVE: To examine whether the addition of counseling, medical care, and psychosocial services improves the efficacy of methadone hydrochloride therapy in the rehabilitation of opiate-dependent patients.
DESIGN: Random assignment to one of three treatment groups for a 6-month clinical trial: (1) minimum methadone services (MMS)--methadone alone (a minimum of 60 mg/d) with no other services; (2) standard methadone services (SMS)--same dose of methadone plus counseling; or (3) enhanced ...
|Known for Psychosocial Services | Methadone Counseling | Substance Abuse Treatment | Random Assignment | Opiatedependent Patients|
We performed a double-blind, placebo-controlled, randomized 12-week trial of desipramine hydrochloride treatment of cocaine dependence among methadone-maintained patients. Fifty-nine patients completed the 12-week medication trial (36 received desipramine and 23 received placebo), and 94% were recontacted 1, 3, and 6 months after treatment. There were significantly more dropouts in the desipramine than in the placebo group. Baseline to 12-week comparisons of Addiction Severity Index ...
|Known for Desipramine Treatment | Cocaine Dependence | Maintained Patients | Groups Placebo | Substance Disorders|
DESIGN: 118 ASI-6 recent status items were subjected to nonparametric item response theory (NIRT) analyses followed by confirmatory factor analysis (CFA). Generalizability and concurrent validity of the derived scores were determined.
SETTING AND PARTICIPANTS: A total of 607 recent admissions to variety of substance abuse treatment programs constituted the derivation ...
|Known for Addiction Severity | Status Scores | Version 6 | Concurrent Validity | Substance Disorders|
Is the Addiction Severity Index a Reliable and Valid Assessment Instrument Among Clients with Severe and Persistent Mental Illness and Substance Abuse Disorders?
[ PUBLICATION ]
Objective: This study examined aspects of reliability, validity and utility of Addiction Severity Index (ASI) data as administered to clients with severe and persistent mental illness (SMI) and concurrent substance abuse disorders enrolled in a publicly-funded community mental health center. Methods: A total of 62 clients with SMI volunteered to participate in an interobserver and test-retest reliability study of the ASI. Spearman-Brown and Pearson correlation coefficients were ...
|Known for Addiction Severity | Mental Illness | Composite Scores | Substance Abuse | Dual Psychiatry|
Comparative Effectiveness and Costs of Inpatient and Outpatient Detoxification of Patients with Mild-to-Moderate Alcohol Withdrawal Syndrome
[ PUBLICATION ]
We compared the effectiveness, safety, and costs of outpatient (n = 87) and inpatient (n = 77) detoxification from alcohol in a randomized, prospective trial involving 164 male veterans of low socioeconomic status. The outpatients were evaluated medically and psychiatrically and then were prescribed decreasing doses of oxazepam on the basis of daily clinic visits. The inpatient program combined comprehensive psychiatric and medical evaluation, detoxification with oxazepam, and the ...
|Known for Alcohol Withdrawal | Outpatient Detoxification | Process Assessment | Medical Complications | Follow Studies|
Five year outcomes in a cohort study of physicians treated for substance use disorders in the United States
[ PUBLICATION ]
OBJECTIVE: To evaluate the effectiveness of US state physician health programmes in treating physicians with substance use disorders.
DESIGN: Five year, longitudinal, cohort study.
SETTING: Purposive sample of 16 state physician health programmes in the United States.
PARTICIPANTS: 904 physicians consecutively admitted to one of the 16 programmes from September 1995 to September 2001.
MAIN OUTCOME MEASURES: Completion of the programme, continued alcohol and drug misuse (regular urine ...
|Known for United States | Substance Disorders | Year Outcomes | Health Physicians | Drug Misuse|
[ PUBLICATION ]
There is national concern regarding the problems of alcohol and drug abuse and the adequacy and quality of the national addiction treatment system, particularly for adolescents. This article reviews the published literature evaluating the ability of health, education, and specialty treatment systems to identify and treat affected adolescents and adults. A separate section reviews the status of the national treatment system for adults through findings from a nationally representative ...
|Known for Adolescents Adults | Addiction Treatment | Substance Abuse | Disorders Adolescent | Quality Health|
INTRODUCTION: Physicians with substance use disorders receive care that is qualitatively different from and reputedly more effective than that offered to the general population, yet there has been no national study of this distinctive approach. To learn more about the national system of Physician Health Programs (PHPs) that manage the care of addicted physicians, we surveyed all 49 state PHP medical directors (86% responded) to characterize their treatment, support, and monitoring ...
|Known for Addicted Physicians | Physician Health | 5 Years | Substance Disorders | National Study|
The Addiction Severity Index (ASI) is an instrument widely used to assess the treatment problems of substance users. Its psychometric properties have been tested and found satisfactory for many types of substance abusers entering treatment. However, there are many other subgroups of substance users not in formal treatment, such as homeless substance users. While the ASI has been used with this subgroup, its psychometric properties remain questionable. This study examined the reliability ...
|Known for Addiction Severity | Reliability Validity | Substance Users | Psychometric Properties | Composite Scores|